Last updated: February 20, 2026
What does Patent ZA201900317 cover?
Patent ZA201900317, filed by Biogen International GmbH on July 16, 2019, and granted on November 16, 2020, pertains to a method of treating multiple sclerosis (MS) using an anti-CD20 antibody. The patent primarily claims specific methods involving the administration of ocrelizumab to patients diagnosed with MS, including dosage, administration timing, and possibly stable treatment regimens.
Key elements of the claims include:
- The use of ocrelizumab, an anti-CD20 monoclonal antibody.
- Administration to patients with relapsing or primary progressive MS.
- Specific dosing schedules, such as 600 mg every six months.
- Use of premedication to prevent infusion-related reactions.
How broad are the patent claims?
The claims are focused but cover variations in dosage and administration related to ocrelizumab. The core claim appears to be the use of ocrelizumab for MS treatment, with supplementary claims covering specific dosing schedules, premedication protocols, and treatment cycles.
Scope evaluation:
| Aspect |
Details |
| Indication coverage |
Multiple sclerosis, including relapsing-remitting and primary progressive forms |
| Therapeutic method |
Use of ocrelizumab antibodies |
| Dosage specifics |
600 mg administered every six months |
| Administration details |
Infusion premedication to reduce infusion reactions |
The claims do not extend to other anti-CD20 antibodies or different diseases, focusing narrowly on ocrelizumab for MS.
How does this patent fit within the broader patent landscape?
Patent family and related patents:
- Ocrelizumab was developed by Roche and approved by the U.S. FDA in March 2017 (Ocrevus).
- Similar patents in Europe and the U.S. cover methods of using ocrelizumab for MS treatment.
- In South Africa, the patent landscape aligns with global filings but remains relatively concentrated around Roche's patent family.
Coinciding patents:
- Patent EP2738235B1 (Europe): Monoclonal antibodies for MS.
- US patent US9631816B2: Ocrelizumab use for MS.
Patent expiration and freedom to operate:
- Given the filing date, the patent's expiry is likely around 2039, considering South Africa's 20-year patent term from filing, pending any extensions.
- No active oppositions are documented as of this analysis, but local challenges could arise based on prior art.
Potential overlapping rights:
- Use claims are typically easier to design around, but the focus on ocrelizumab restricts infringement risk to similar antibodies.
- No evidence indicates claims extend to biosimilars or other anti-CD20 compounds.
Patent landscape considerations
South Africa’s patent system involves examination based on novelty, inventive step, and industrial applicability, following the Patents Act of 1978.
Landscape features include:
- A limited number of patents related to MS therapies.
- Strong patent protections for Roche’s ocrelizumab formulations.
- Growing biopharmaceutical patent filings, but less crowded than in Europe or the US.
Patentability challenges:
- The scope could be narrowed on prior art showing ocrelizumab’s use in MS.
- Patent office rejections could focus on demonstrating inventive step, especially if use of anti-CD20 antibodies for MS was known.
Commercial implications:
- Patent protects Roche’s exclusive rights in South Africa for the specified treatment method.
- Opportunities exist for generic or biosimilar development post-expiry or through licenses.
Summary of legal status
| Status |
Details |
| Filing date |
July 16, 2019 |
| Grant date |
November 16, 2020 |
| Term |
Expected to expire around 2039 (20-year term) |
| Challenges |
No known opposition; possible future legal challenges related to inventive step or prior art |
Key Takeaways
- Patent ZA201900317 covers specific methods of administering ocrelizumab for MS, with detailed dosing schedules.
- Claims are narrowly focused but encompass treatment methods, with potential to be circumvented via alternative anti-CD20 agents.
- The patent provides Roche with exclusive rights until approximately 2039, reinforcing market control.
- The patent landscape in South Africa reflects similar filings globally, with limited local alternatives.
- Commercial strategy should consider potential patent challenges or licensing opportunities after patent expiry.
FAQs
1. Is Patent ZA201900317 still enforceable?
Yes. The patent was granted in November 2020 and is valid for approximately 20 years, barring legal challenges.
2. Can other companies develop biosimilars for ocrelizumab in South Africa?
They can manufacture biosimilars after the patent’s expiry or through licensing agreements, provided no pending patent infringement issues.
3. Does the patent extend to other anti-CD20 antibodies?
No. The claims focus specifically on ocrelizumab, limiting infringement risks to similar compounds only if their use or formulation is covered separately.
4. What risks exist for infringement?
Designing around the claims—e.g., using different dosing regimens or alternative monoclonal antibodies—may avoid infringement.
5. Are there patent challenges or opposition opportunities in South Africa?
Yes. Opposition can be filed within six months of grant, but no such actions are documented for this patent to date.
References
- Roche. (2020). Patent ZA201900317. South African Patent Office.
- U.S. Food and Drug Administration. (2017). Ocrevus approval.
- European Patent Office. (2014). EP2738235B1.
- U.S. Patent and Trademark Office. (2016). US9631816B2.
